388 related articles for article (PubMed ID: 37445684)
1. Generation and Functional Characterization of Anti-CD19 Chimeric Antigen Receptor-Natural Killer Cells from Human Induced Pluripotent Stem Cells.
Klaihmon P; Kang X; Issaragrisil S; Luanpitpong S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445684
[TBL] [Abstract][Full Text] [Related]
2. Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells.
Klaihmon P; Luanpitpong S; Kang X; Issaragrisil S
Cancer Cell Int; 2023 Nov; 23(1):297. PubMed ID: 38012684
[TBL] [Abstract][Full Text] [Related]
3. Selective Cytotoxicity of Single and Dual Anti-CD19 and Anti-CD138 Chimeric Antigen Receptor-Natural Killer Cells against Hematologic Malignancies.
Luanpitpong S; Poohadsuan J; Klaihmon P; Issaragrisil S
J Immunol Res; 2021; 2021():5562630. PubMed ID: 34337077
[TBL] [Abstract][Full Text] [Related]
4. CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia.
Yang N; Zhang C; Zhang Y; Fan Y; Zhang J; Lin X; Guo T; Gu Y; Wu J; Gao J; Zhao X; He Z
J Transl Med; 2024 Mar; 22(1):274. PubMed ID: 38475814
[TBL] [Abstract][Full Text] [Related]
5. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.
Li Y; Hermanson DL; Moriarity BS; Kaufman DS
Cell Stem Cell; 2018 Aug; 23(2):181-192.e5. PubMed ID: 30082067
[TBL] [Abstract][Full Text] [Related]
6. Targeted integration of EpCAM-specific CAR in human induced pluripotent stem cells and their differentiation into NK cells.
Tang SY; Zha S; Du Z; Zeng J; Zhu D; Luo Y; Wang S
Stem Cell Res Ther; 2021 Nov; 12(1):580. PubMed ID: 34802459
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
Rafei H; Daher M; Rezvani K
Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
[TBL] [Abstract][Full Text] [Related]
8. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract][Full Text] [Related]
9. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
Front Immunol; 2019; 10():3123. PubMed ID: 32117200
[TBL] [Abstract][Full Text] [Related]
10. CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment.
Kong D; Kwon D; Moon B; Kim DH; Kim MJ; Choi J; Kang KS
Biomed Pharmacother; 2024 May; 174():116436. PubMed ID: 38508081
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies.
Tanaka J
Hematol Oncol; 2021 Feb; 39(1):11-19. PubMed ID: 32905618
[TBL] [Abstract][Full Text] [Related]
12. IPSC-derived CAR-NK cells for cancer immunotherapy.
Lin X; Sun Y; Dong X; Liu Z; Sugimura R; Xie G
Biomed Pharmacother; 2023 Sep; 165():115123. PubMed ID: 37406511
[TBL] [Abstract][Full Text] [Related]
13. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells.
Roex G; Campillo-Davo D; Flumens D; Shaw PAG; Krekelbergh L; De Reu H; Berneman ZN; Lion E; Anguille S
J Transl Med; 2022 Mar; 20(1):124. PubMed ID: 35287669
[TBL] [Abstract][Full Text] [Related]
14. CAR-NK cells from engineered pluripotent stem cells: Off-the-shelf therapeutics for all patients.
Lu SJ; Feng Q
Stem Cells Transl Med; 2021 Nov; 10 Suppl 2(Suppl 2):S10-S17. PubMed ID: 34724715
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy.
Chaudhry K; Dowlati E; Bollard CM
Expert Rev Clin Immunol; 2021 Jun; 17(6):643-659. PubMed ID: 33821731
[No Abstract] [Full Text] [Related]
16. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells.
Herrera L; Santos S; Vesga MA; Anguita J; Martin-Ruiz I; Carrascosa T; Juan M; Eguizabal C
Sci Rep; 2019 Dec; 9(1):18729. PubMed ID: 31822751
[TBL] [Abstract][Full Text] [Related]
17. CAR T cells: Building on the CD19 paradigm.
Globerson Levin A; Rivière I; Eshhar Z; Sadelain M
Eur J Immunol; 2021 Sep; 51(9):2151-2163. PubMed ID: 34196410
[TBL] [Abstract][Full Text] [Related]
18. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.
Soldierer M; Bister A; Haist C; Thivakaran A; Cengiz SC; Sendker S; Bartels N; Thomitzek A; Smorra D; Hejazi M; Uhrberg M; Scheckenbach K; Monzel C; Wiek C; Reinhardt D; Niktoreh N; Hanenberg H
Front Immunol; 2022; 13():847008. PubMed ID: 35464442
[TBL] [Abstract][Full Text] [Related]
19. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.
Oei VYS; Siernicka M; Graczyk-Jarzynka A; Hoel HJ; Yang W; Palacios D; Almåsbak H; Bajor M; Clement D; Brandt L; Önfelt B; Goodridge J; Winiarska M; Zagozdzon R; Olweus J; Kyte JA; Malmberg KJ
Cancer Immunol Res; 2018 Apr; 6(4):467-480. PubMed ID: 29459477
[TBL] [Abstract][Full Text] [Related]
20. iPSC-derived NK cells with site-specific integration of CAR19 and IL24 at the multi-copy rDNA locus enhanced antitumor activity and proliferation.
Zhang Y; Shi Q; Wang P; Huang C; Tang S; Zhou M; Hu Q; Wu L; Liang D
MedComm (2020); 2024 May; 5(5):e553. PubMed ID: 38737469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]